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Preterm birth is the most common reason for perinatal morbidity and mortality in the western world. It has been shown that
in euthyreotic pregnant women with thyroid autoimmune antibodies, L-Thyroxine replacement reduces preterm delivery rate in
singleton pregnancies. We investigated in a nonrandomized retrospective observational study whether L-Thyroxine replacement,
maintaining maternal free thyroxine serum level in the high normal reference range prescribed for nonpregnant women also
inﬂuences the rate of preterm delivery in women without thyroid autoimmune antibodies. As control group for preterm delivery
rate, data from perinatal statistics of the State of Baden-W¨ urttemberg from 2006 were used. The preterm delivery rate in the
study group was signiﬁcantly reduced. The subgroup analysis shows no diﬀerence in primiparous but a decline in multiparous
by approximately 61% with L-Thyroxine replacement. Maintaining free thyroxine serum level in the high normal reference range
prescribed for nonpregnant women may reduce the preterm delivery rate.
1.Introduction
Theprevalenceofpretermbirth,deﬁnedasdeliverybefore37
completed weeks’ gestation, varies from 6% to 15%, depend-
ing on geographical and demographic features of the popu-
lation studied. Preterm births account for 75% of perinatal
deaths, with over two-thirds of these arising in preterm
infants delivered before 32 weeks’ gestation. In 2002, this was
themostfrequentcauseofneonataldeathsintheUSA.65%–
75% of preterm births are deﬁned as spontaneous preterm
births caused by spontaneous preterm labor or preterm pre-
mature rupture of the membranes and 30%–35% of preterm
deliveries are medically indicated due to maternal or fetal
complications in pregnancy. About one-quarter of preterm
births occur in multiple pregnancies [1–5].
Various epidemiological risk factors were identiﬁed.
These encompass advanced age or teenage pregnancy, parity,
race,historyofcervicalconebiopsy,lowbodymassindex,to-
bacco use, assisted conception with in vitro fertilisation, and
gamete intrafallopian transfer, especially for singleton gesta-
tions, systemic and genital-tract infection, and low parental
socioeconomic status, this being the most important factor
[1–4, 6]. Thanks to advances in neonatal medicine, the out-
come for preterm infants born at or after 32 weeks’ gesta-
tion is similar to that of full-term infants. Limits of viability
have been lowered to a gestational age (GA) as low as 23
weeks at the expense of physical disabilities and long-term
neurodevelopmental consequences [2, 4, 5, 7].
Thyroid hormones are essential for diﬀerentiation and
maturation of the fetus and placenta and are especially im-
portant for the development of the fetal central nervous
system. Epidemiological studies have demonstrated that the
intelligence quotient (IQ) of the oﬀspring correlates with
maternal free thyroxine (fT4) serum level. The higher ma-
ternal fT4, the higher the IQ of the oﬀspring [8–13]. In a
study with euthyroid thyroid peroxidase antibody (TPOAb)
positive pregnant women receiving substitution with L-
Thyroxine(L-T4)itprovedpossibletodecreasetheirpreterm
birth rate [14–16]. Thyroid hormones may also provide pro-
tection against preterm delivery in women without TPOAb.2 Journal of Thyroid Research
The aim of this study is to investigate whether L-T4
replacement therapy by maintaining maternal fT4 in the
high normal reference range prescribed for nonpregnant
women can also lower the preterm birth rate in pregnant
women who do not have thyroid autoimmune antibodies.
For this purpose, a group of pregnant women, who had been
treated with L-T4 with the goal of elevating maternal fT4
serumleveltothehighnormalreferencerangeprescribedfor
nonpregnant women to achieve an optimal fetal supply with
thyroxine, were retrospectively examined.
2.SubjectsandMethods
This clinical trial is a retrospective nonrandomized obser-
vational study with prospectively designed data. From April
2001 to March 2010, all pregnant women below 12 weeks’
gestation presenting for their ﬁrst medical consultation for
prenatal care in a medical oﬃce were oﬀered a serological
thyroid scan. This included basal TSH, free triiodothyronine
(fT3), free thyroxine (fT4), thyroglobulin antibody test
(TgAb),thyroidperoxidaseantibody test(TPOAb),andTSH
receptor antibody test (TSH-R-Ab).
T h ep r i m a r yo b j e c tw a st oe l e v a t em a t e r n a lf T 4t ot h e
high normal reference range for nonpregnant adults in order
to optimise fetal brain development. For this purpose, and
for better interpretation, the normal reference range for
nonpregnant adults (fT4 12.14–19.62pmol/L) was divided
into thirds. The division was made as follows: the lower third
ranged from 12.14–14.72pmol/L, the middle third ranged
from 14.72–17.17pmol/L, and the upper third ranged from
17.17–19.62pmol/L. All women with an fT4 serum level
in the lower and middle third of the reference range for
nonpregnant adults at the ﬁrst consultation were given a
variable dose of L-T4, usually starting with 25µg–50µgL -
T4 per day, after informed consent, to raise the fT4 serum
level in the high normal reference range (upper third) for
nonpregnant adults. All women with a physiological fT4
serum level in the high normal reference range (upper
third) for nonpregnant adults at the ﬁrst consultation were
only serological assessed and L-T4 therapy was started later
when serum fT4 declined to the middle or lower third.
Additionally, each woman received supplements containing
200µg iodide and 400µg folic acid.
Maternal fT4 serum levels were regularly assessed after
an interval of 24 hours from the last L-T4 intake every
4 weeks during routinely performed serological scans for
pregnancy care and if necessary, the L-T4 dose was adjusted.
For adjustment, a variable dosage for example, between 25–
50µg/die L-T4 was usually applied. If the increased dose was
not tolerated, it was recommended to continue with the last
tolerated dose and to increase it one week later. TSH was
not further assessed because the goal was to avoid a low
maternalfT4serumlevelinpregnancyforoptimalfetalbrain
development, and a decline of the fT4 serum level is not
automatically accompanied by an increase of the TSH level.
Furthermore, maternal TSH is not related to the cognitive
competence of the oﬀspring [12]. Moreover, in pregnancy,
TSH shows dependencies with other pregnancy-associated
hormonal ﬂuctuations and the interval between two blood
samples of 4 weeks is too short for precise TSH readings
[17]. Thyroid function control was handled by determining
fT4 and not TSH as is the case when assessing central
hypothyroidism [18–20].
Prenatal care included measurement of body weight,
blood pressure, urinary test for protein, glucose, blood,
and nitrite. Check intervals were as follows: every 4 weeks
until the 30 weeks’ gestation, thereafter every 3 weeks,
weekly after the 35 weeks’ gestation, and after term every
2 days. Beginning at 20 weeks’ gestation a digital vaginal
examination was performed, and if necessary an ultrasound
scan of the cervix length was done.
Ultrasound scans were performed between gestation
weeks 9–12, 19–22, and 29–32. If required, color Doppler
sonography and special ultrasound scan to rule out fetal
malformation were undergone. A cardiotocographic survey
of the fetus was routinely started at 28 weeks’ gestation and
thereafter at each visit.
Women who developed preterm labor were treated
with orally applied magnesium. In case of hospitalisation,
treatment of preterm labor was performed according to
hospital guidelines, for example, bed rest, intravenous ﬂuids,
tocolytic therapy, and steroid administration, if clinically
indicated. Administration of L-T4 was continued during
treatment for preterm labor.
All pregnant women were delivered in an obstetric unit
in diﬀerent hospitals in the vicinity. Routinely, the newborns
were medically examined by the gynaecologist who had
assisted parturition immediately after birth. Apgar score
and arterial blood gas analysis from the umbilical cord
were measured. A further examination of the newborn was
performedbyapaediatricianbetweenthe3rd–7thdayoflife.
Afterdischarge,allchildreninGermanyhaveregularmedical
checkupsperformedbyapaediatricianorfamilyphysicianin
privateoﬃceinregularintervalsbeginningat4–6weeksafter
birth until adolescence. 6–8 weeks postpartum all women
had a medical check for controlling uterine involution and
after establishing normal serum fT4 levels, L-T4 substitution
was discontinued.
The study group included all women who fulﬁlled the
following criteria: women with singleton pregnancies who
had their ﬁrst antenatal check before the 12 weeks’ ges-
tation, determined by ultrasound (crown-rump length). The
women presented regularly for inspection until birth. Since
this clinical trial was designed as a retrospective nonran-
domized observational study, we chose a surrogate as control
group.ThestudywasperformedintheStateofBaden-W¨ urt-
temberg, so we used as control group the preterm delivery
rate from all 87.897 singleton pregnancies of the State of
Baden-W¨ urttemberg, Germany, in the year 2006, collected
in central database (GeQiK) with unknown thyroid status.
The processed data, provided to us by the database GeQik
of the perinatal statistics of the State of Baden-W¨ urttemberg
were related to preterm birth rate, maternal age and parity
status. A further comparison of more obstetrical details
and perinatal outcomes was not possible to realize. Preterm
delivery was deﬁned as parturition before completion of the
37 weeks’ gestation.Journal of Thyroid Research 3
3.LaboratoryAnalysis
Serum basal TSH and fT4 were measured using a third gen-
eration electrochemiluminescence immunoassay (Elecsys
1010/2010–MODULAR ANALYTICS E170 from Roche Di-
agnostics GmbH–Mannheim, Germany). Reference val-
ues for TSH were 0.27–4.2µIU/mL and for fT4 12.14–
19.62pmol/L. Intra- and interassay coeﬃcients of variation
were 3.0% and 7.2% for TSH, and 1.4% and 3.5% for fT4.
Thyroid antibodies were also determined using the above-
mentioned analytic test. Thyroid antibody titers were con-
sidered positive for TPO-Ab titers above 34U/mL, for Tg-
Ab titers above 115U/mL, and for the anti-TSH receptor-Ab
titers above 2.0U/L.
4.StatisticalAnalysis
Basisfordataofthecontrolgrouparepopulationparameters
statistical analysis took place by calculating the 99% conﬁ-
dence intervals (99%-CI) of the values in the study group.
5. Results
Between April 2001 and March 2010, 771 pregnant women
presentedformedicalcare.Amongthese,96(13%)hadaﬁrst
trimester abortion, 12 (2%) moved away to other regions, 18
(2%) had multiple pregnancy, 87 (11%) presented after 12
weeks’ gestation. 558 (72%) women met the study inclusion
criteria, being under 12 weeks’ gestation with singleton
pregnancy.
Among these 558 women there were 108 (19%) women
with autoimmune thyroid antibodies, 43 primiparous, and
65 multiparous. By taking away these 108 women, there
remained450womenwithoutautoimmunethyroidantibod-
ies deﬁning the study group.
Regarding the distribution of maternal age and parity
status (primiparous versus multiparous), the study group
and control group were almost identical. In the study
group, 39.8% were primiparous versus 39.2% in control
group, and 60.2% were multiparous in study group versus
60.8% in control group. Dictated by body mass index
(BMI), 61% of the primiparous group had normal weight
at ﬁrst consultation, and 39% were overweight or obese.
Of the multiparous group, 60% had normal weight at ﬁrst
consultation and 40% were overweight or obese. There was
a similar mean weight gain of 10–15kg for primiparous and
multiparous in pregnancy.
Peripartum outcome and fetal outcome resulted as
follows: 68% of primiparous and 73% of multiparous had
vaginal delivery within the study group. Cesarean section
occurred in 34% of the primiparous (15% were elective,
and 19% were emergency cesarean section) and in 28%
of the multiparous (17% were elective, and 11% were
emergency cesarean section). Pregnancy-induced hyperten-
sion occurred in 9 (2%) women of the study group (5
primiparous and 4 multiparous). Data from 2 women (1
primiparous and 1 multiparous) are missing. In the study
group 22 (4.8%) women had breech presentation at term (11
were primiparous and 11 were multiparous).
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Figure 1: Percentage distribution of the reasons for referral of
newborns in a paediatric hospital (n = 35). Preterm births are not
shown.
Data for Apgar score and arterial umbilical cord pH were
almost complete. There is data missing for 2 Apgar scores
and 8 arterial umbilical cord pHs. An Apgar score below 3, as
a sign of impaired vitality was not registered at all and only
2 (0.5%) newborns had an arterial umbilical cord pH below
7.00, demonstrating asphyxia.
Apartfrompretermbirthsthatwereallreferredtoapedi-
atric hospital, further 35 newborns were referred to a pedi-
atric hospital, 18 (11%) born by primiparous, and 17 (6%)
born by multiparous.
Reasons for newborn referral to a pediatric hospital are
listed in Figure 1.
Thyroid status of the study group is presented as shown
in Figure 2. Only 16% of primiparous and 18% of mul-
tiparous had fT4 serum level in the high normal ref-
erence range prescribed for nonpregnant women at ﬁrst
consultation.
Preterm birth rate was ﬁrst evaluated for the whole study
group and separately depending on parity status, primipa-
rous versus multiparous.
In the study group there were 20 preterm births (4.4%),
13 in primiparous (7.3%) and 7 in multiparous (2.6%). The
gestational age of the preterm deliveries is shown in Table 1.
70% of preterm births from the study group were spon-
taneouspretermbirthscausedbyspontaneouspretermlabor
or preterm premature rupture of the membranes and 30%
of preterm births were medically indicated by pregnancy-
induced hypertension, HELLP syndrome, ovarian tumor,
and acute pancreatitis concurring with obesity.
Preterm birth rate in the study group was 4.4% (99%-CI
1.9%–6.9%) versus 7.1% in the control group corresponding
to a reduction of 38%. The subgroup analysis, according to
parity status showed a preterm birth rate for primiparous
in the study group of 7.3% versus 7.6% in the control
group, and for multiparous a preterm birth rate of 2.6% in
studygroup(99%-CI0.1%–5.1%)versus6.7%inthecontrol
group, respectively (Table 2).4 Journal of Thyroid Research
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Figure 2: Percentage distribution of maternal fT4 serum level at
ﬁrst consultation subdivided into lower third, middle third and
upper third of the reference range for nonpregnant women (n =
450).
Table 1: Numbers of preterm births plotted on gestational week
and parity status the study group (n = 450).
Weeks’ GA <31+ 6 32 +0 −33+ 6 34 +0 −37+ 0
Primiparous 1 3 9
Multiparous 2 1 4
Table 2: Percentage of preterm birth rates plotted on parity status
in the study group and control group.
Total Primiparous Multiparous
Study group 4.4% 7.3% 2.6%
Control group 7.1% 7.6% 6.7%
Thus, the reduction of preterm birth rate by maintaining
maternal fT4 serum level in pregnancy in the high normal
reference range prescribed for nonpregnant women is eﬀec-
tive in multiparous but not in primiparous. The preterm
birth rate dropped by approximately 61% in the multiparous
of the study group.
Since there was no ﬁxed dosage for L-T4 therapy and
patients were advised to maintain the dosage unchanged
in case of intolerance when dose augmentation had to
occur, side eﬀects were rarely noted. Nevertheless, if patients
experienced adverse reactions, the L-T4 dose was reduced.
Moreover, undesirable side eﬀects for the fetus and newborn
such as tachycardia or other signs of induced hyperthy-
roidism did not occur at all and were not recorded during
cardiotocographic controls. Due to the variable L-T4 dose
and the intake regime, L-T4 was well tolerated by pregnant
womenandcomplaintssuchaspalpitations,tachycardia,and
other undesirable clinical signs of hyperthyroidism were very
rare and transient. However, pregnancy-associated nausea
was more pronounced, predominantly in the ﬁrst trimester.
6. Discussion
Toourknowledgethisistheﬁrststudypresentinganessential
beneﬁt for reducing preterm birth rate in euthyroid mul-
tiparous women without thyroid autoimmune antibodies
by keeping maternal fT4 serum level in the high normal
reference range prescribed for nonpregnant women with
L-T4 substitution. The preterm birth rate for multiparous
in the study group declined by 61%. Primiparous did not
beneﬁt from L-T4 therapy. Possibly, the pathomechanism
of preterm birth is essentially diﬀerent among primiparous
compared to multiparous, which would imply the necessity
of diﬀerent therapeutic strategies.
These results are in contrast to two other studies. Casey
et al. found no mentionable risk for pregnancy outcome
if the fT4 serum level was found to be in the lowest
third of the gestational age speciﬁc reference range. Clearly,
Goldman et al. recently compared pregnancy outcome in
women with subclinical hypothyroidism and in women with
hypothyroxinaemia deﬁned as fT4 serum level below the
2.5th percentile. They failed to determine a link between
subclinical hypothyroidism and adverse pregnancy outcome
and hypothyroxinemia was not associated with the majority
of pregnancy complications [21, 22].
In this study, a high maternal fT4 serum level decreased
preterm birth rate in multiparous by yet unknown mech-
anisms. In some studies, it has been shown that human
chorionic gonadotropin (hCG) plays a part in maintenance
of uterine quiescence in the third trimester, and hence could
be an endogenous tocolytic agent. HCG exerts a potent
myometrial relaxant eﬀect in human myometrium in the
third trimester and inhibits preterm delivery in animals.
Thyroid hormone stimulates the synthesis of hCG and the
level of serum thyroid hormone is a positive regulator of
serum thyrotropin bioactivity. Due to the fact that TSH and
hCG share a certain similarity, being members of the same
glucoprotein family, it appears possible that serum thyroid
hormonescanalsopositivelyregulatehCGbioactivity,which
in turn increases the biological eﬀects on the myometrium
until parturition [1, 4, 14, 23].
T h es t u d yg r o u pr e c e i v e dL - T 4s u b s t i t u t i o nt oa v o i da
low maternal fT4 serum level for an optimal fetal brain
development. The prevalence of low maternal fT4 levels
is probably 150–200 times more common than congenital
hypothyroidism [24, 25]. It was demonstrated that if mater-
nal serum fT4 is low, fetal T3 levels in the brain will be low
even in the presence of normal maternal and fetal serum
fT3, suggesting that both T3 and T4 in the fetal brain are
dependant on maternal fT4. Low maternal fT4 serum levels
could have detrimental eﬀects on fetal brain development.
In animal experiments, it was demonstrated that even a
modest and transient decrease in maternal fT4 resulted in
altered brain histogenesis and cytoarchitecture of the fetal
cerebral cortex [26, 27] .V a r i o u so b s e r v a t i o n a ls t u d i e sh a v e
shownthatmaternalsubclinicalhypothyroidismandlowfT4
serum levels caused a signiﬁcant decrease in IQ scores of the
progeny. [8–11, 28–36]. In contrast to these ﬁndings, only
one study failed to ﬁnd an association between maternal
thyroid function and cognitive test scores in children [37].
Handling thyroid function control by assessing only fT4
for a goal-oriented value as was done in this study and which
is similar to controlling central hypothyroidism carries the
risktooverdosageL-T4andtoprovokepotentiallymetabolic
hyperthyroidism. The usual assessment of an adequate L-T4Journal of Thyroid Research 5
doseinreplacementtherapyisdonebydeterminingTSHand
fT4 levels, preferably in a blood sample taken before inges-
tion of the subsequent L-T4 dose [38]. In nonpregnant states
it takes 6–9 weeks and more to normalize a suppressed TSH
value typically found when initiating L-T4 administration.
As a consequence, it has been shown that patients taking 100
to 150µg/d of L-T4 have a nearly 50% probability that serum
TSH will be undetectable [39]. Determining TSH below an
interval of 6–9 weeks wouldbe likely to result in a suppressed
TSH level but would not necessarily be accompanied by an
fT4serumlevelintheupperthirdofthereferencerange[40].
Furthermore, L-T4 replacement therapy is commonly
associated with supraphysiologically high fT4 and low fT3
serum levels, in general without hyperthyroid symptoms.
Since fT3 serum level is maintained within normal limits
by decreased peripheral conversion of the prohormone L-
T4,supraphysiologicalfT4serumlevelsarenotconsideredto
be harmful. Therefore, supraphysiological serum fT4 levels
in patients taking L-T4 are not necessarily accompanied by
clinical consequences, if there are no signs or symptoms of
clinical toxicity. Clinical experience with pregnant women
on TSH suppressive thyroid therapy after thyroid cancer
treatment does not appear to indicate any complications
[41,42].SilvaandLarsonhaveshownthatT4ispreferentially
converted to T3 in the pituitary gland to a greater degree
than in other tissues, so that its TSH suppressive eﬀect is
greater than its metabolic eﬀect. In other words, exogenously
administered L-T4 suppresses both the pituitary gland and
the thyroid gland as well [43].
In contrast to supraphysiological fT4 serum concentra-
tion seen in L-T4 replacement therapy, hyperthyroidism is
deﬁned as an excessive thyroid hormone production due
to thyroid overactivity. The vast majority of cases of hy-
perthyroidism in pregnancy are induced by Graves’ disease,
toxic adenoma, or thyroid hormone resistance, where the
negative feedback mechanism no longer functions. In these
pathological conditions the overactive thyroid gland secretes
both the metabolically inactive prohormone T4 and the
metabolically highly active hormone T3 causing multiple
symptoms. In Graves’ disease, the intrathyroidal type-II
deiodinase (D2), which activates thyroid hormone, has a 50
to 150 fold higher activity than in placenta and contributes
signiﬁcantly to the intrathyroidal T3 production and secre-
tion [44]. Hyperthyroidism caused by Graves’ disease and
toxic multinodular goiter, high T3 concentrations are the
result of excessive production and release from the thyroid
gland and not of peripheral deiodination [45]. This explains
why patients with Graves’ disease or with toxic adenoma
present symptoms of hyperthyroidism in contrast to patients
taking L-T4 in a TSH suppressive dose. Additionally, in
replacement therapy with a TSH suppressive L-T4 dose, T3
is derived completely from peripheral monodeiodination in
the liver, kidney, or muscle because the thyroid gland is also
suppressed. To achieve physiological levels of T3 in humans
treated with L-T4, it is necessary to maintain fT4 levels at
the higher end of the normal range [46, 47]. Only under
pathological conditions, such as massive metastatic follicular
thyroid cancer has T3 thyrotoxicosis by increased conversion
of administered L-T4 been described [48]. L-T4 replacement
therapy is associated with supraphysiologically high fT4 and
low fT3 serum levels without hyperthyroid symptoms, since
the fT3 serum level is maintained within normal limits by
decreased peripheral conversion of the prohormone L-T4.
This metabolic variance constitutes a fundamental diﬀerence
between endogenously produced thyroid hormones T4 and
especially T3 and exogenously administered thyroid hor-
mone like L-T4. L-T4 has a safe latitude in dosage and even
after massive acute ingestion only minimal symptoms are
seen as the peak T3 level does not exceed the upper reference
range limit, while fT4 and the metabolically inactive rT3
show very high serum levels [41, 43, 45, 47, 49–56].
Thyroid hormones are the most prescribed drugs world-
wide and are considered to be safe. Relevant adverse eﬀects
are usually manifested in older patients. Disputable side
eﬀectsare the risk of atrial ﬁbrillation in patients with intrin-
sic heart disease and increased bone loss in postmenopausal
women [57, 58].
Since there was no ﬁxed dose regimen for L-T4 therapy
in the study group, patients were advised to maintain their
dosage unchanged in case of intolerance, and when dose
augmentation proved necessary, side eﬀects rarely occurred
and in none L-T4 had to be discontinued. Nevertheless, if
patients experienced adverse reactions the L-T4 dose was
reduced. Moreover, undesirable side eﬀects for the fetus
and newborn such as tachycardia or other signs of induced
hyperthyroidism did not occur at all and were not recorded
during cardiotocographic controls. However, pregnancy-
associated nausea was more pronounced, predominantly in
the ﬁrst trimester in only a few women. By reducing the L-T4
dosage, pregnancy-associated nausea resolved.
7. Conclusion
In summary, thyroid hormone replacement therapy aiming
at holding maternal fT4 serum levels in the upper third of
the reference range prescribed for nonpregnant women and
controlling this therapy by determining fT4 seems to be safe
andtohavebeneﬁcialeﬀectsforbothmotherandfetus.Inall
probability it will reduce preterm birth rates in multiparous.
These results have yet to be conﬁrmed by further prospective
randomized studies.
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